Overview Request Sample Pages Request Customization Download PDF
You are viewing: France Immunoassay Market analysis
Part of: Immunoassay Market (Global)

The France Immunoassay Market was valued at $1316.11 Million in 2025 and projected to reach to $1854.62 Million by 2030, representing a compound annual growth rate of 7.1%. France's immunoassay market is poised for sustained growth through 2030, driven by increasing prevalence of chronic diseases, aging population demographics, and rising healthcare expenditure.

France Immunoassay Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

France Immunoassay Market Trends and Insights

  • This represents a compound annual growth rate (CAGR) of 7.1%, outpacing the global average and reflecting strong demand for diagnostic solutions across France's advanced healthcare infrastructure.
  • France's immunoassay sector benefits from high healthcare spending, aging demographics, and increasing prevalence of chronic diseases that drive demand for accurate diagnostic testing. The French immunoassay market is characterized by significant investment in laboratory automation and point-of-care testing technologies.
  • France's regulatory environment and emphasis on precision medicine continue to support market expansion through 2030.
  • Key drivers include rising adoption of immunoassay platforms in clinical laboratories, hospitals, and diagnostic centers throughout France, coupled with growing awareness of early disease detection benefits among healthcare providers and patients..

Key Market Statistics

  • CAGR (2025-2030) 7.1% CAGR
  • Market Size, 2025 ~USD 1316.11 Million
  • Forecast, 2030 ~USD 1854.62 Million
  • Country France

France Immunoassay Market Overview

Strong CAGR Outperformance :

France's immunoassay market is growing at 7.1% CAGR from 2025-2030, significantly outpacing the global average of 6.1%, demonstrating robust domestic demand and market resilience.

Substantial Market Expansion :

The French market is projected to grow from USD 1,316.11 million in 2025 to USD 1,854.62 million by 2030, representing an increase of USD 538.51 million over the five-year forecast period.

Advanced Healthcare Infrastructure :

France's well-developed healthcare system and high diagnostic adoption rates drive consistent demand for immunoassay solutions across hospitals, laboratories, and clinical settings.

Diagnostic Innovation Hub :

France's strong pharmaceutical and diagnostics sector, combined with significant R&D investments, positions the country as a key market for next-generation immunoassay technologies and personalized medicine applications.

France Immunoassay Market Dynamics

  • The country's commitment to advanced diagnostic capabilities and integration of automation in laboratory settings will further accelerate market expansion.
  • Additionally, France's participation in European healthcare initiatives and regulatory harmonization creates favorable conditions for market players.
  • The forecast period will likely see increased adoption of point-of-care testing and multiplex immunoassay platforms across French healthcare facilities, supporting the projected 7.1% CAGR..

Market Ecosystem

logo-mobile

IMMUNOASSAY MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
 Provides automated immunoassay testing through the Alinity i and ARCHITECT systems for clinical laboratory and blood screening applications. Improves testing throughput within a compact footprint | Supports broad testing menus | Provides greater walk-away time through automated workflows | Supports consistent and reliable results.
company logo
 Provides automated immunoassay testing through cobas e analyzers using electrochemiluminescence technology across infectious disease, cardiac, endocrine, fertility, and oncology applications. Provides high sensitivity and reproducibility through ECL technology | Supports high-throughput testing | Enables continuous reagent loading during operation | Supports carryover-free sample processing.
company logo
 Provides immunoassay testing through Atellica IM, ADVIA Centaur, and IMMULITE systems across infectious disease, cardiac, endocrine, and reproductive health testing. Supports high immunoassay testing throughput | Enables rapid turnaround for key assays | Provides automated QC and remote monitoring | Supports broad assay menus and scalable laboratory configurations.
company logo
 Provides automated immunoassay testing through DxI and Access analyzers for clinical laboratories with varying testing volumes. Provides high productivity per laboratory footprint | Reduces routine maintenance requirements | Supports remote real-time system monitoring | Enables expanded assay processing and laboratory productivity.
company logo
 Provides Bio-Plex multiplex immunoassays and ELISA-based solutions for biomarker, cytokine, protein, and antibody analysis across research and clinical applications. Enables simultaneous measurement of multiple analytes | Reduces sample volume requirements | Supports high-throughput biomarker analysis | Provides automated data analysis and reproducible assay performance.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

In Vitro Diagnostics

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Dna Microarrays
  • Assay Kits
  • Microarrays
Top Companies
  • ROCHE HOLDINGS AG
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Abbott Laboratories
  • Biomerieux s.a.

    Medical Devices

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Magnetic Resonance Imaging (MRI)
    • Disposable Autoinjectors
    • Pulse Oximeters
    • Blood Pressure Monitors
    Top Companies
    • Medtronic plc
    • Abbott Laboratories
    • Stryker Corporation
    • Becton, Dickinson and Company
    • JOHNSON & JOHNSON

      Key Takeaways

      • France's immunoassay market will grow from USD 1,316.11M (2025) to USD 1,854.62M (2030) at a 7.1% CAGR.
      • France's market growth rate exceeds the global immunoassay CAGR of 6.1%, indicating strong regional demand.
      • France's aging population and chronic disease prevalence are primary drivers of immunoassay adoption.
      • France's advanced healthcare infrastructure and regulatory framework support sustained market expansion through 2030.

      Immunoassay Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment CLIA (Technology)
      Forecast Period 2025–2030
      Growth Rate CAGR of 6.1% from 2025 to 2030
      Largest Segment REAGENTS & KITS (Product)
      Market Size Base Year (Billions) ~USD 35.48 (2025)
      Revenue Forecast (Billions) ~USD 47.7 (2030)
      Segments Covered Product, Type, Purchase Mode, Technology, Specimen, Application

      France Immunoassay Market Report Segmentation

      6 segment dimensions are covered across the global market.

      By Product

      • Analyzers
      • Reagents & Kits

      By Type

      • Clia Reagents & Kits
      • Closed-Ended Systems
      • Elisa Reagents & Kits
      • Elispot Reagents & Kits
      • Ifa Reagents & Kits
      • Open-Ended Systems
      • Other Reagents & Kits
      • Rapid Test Reagents & Kits
      • Western Blot Reagents & Kits

      By Purchase Mode

      • Outright Purchase
      • Rental Purchase

      By Technology

      • Clia
      • Elisa
      • Elispot
      • Ifa
      • Other Technologies
      • Rapid Tests
      • Western Blotting

      By Specimen

      • Blood
      • Other Specimens
      • Saliva
      • Urine

      By Application

      • Allergy Diagnostics
      • Autoimmune Disorders
      • Blood Screening
      • Bone & Mineral Disorders
      • Cardiology
      • Drug Monitoring & Testing
      • Endocrinology
      • Infectious Diseases
      • Newborn Screening
      • Oncology
      • Other Applications

      FRANCE: IMMUNOASSAY MARKET, BY END USER, 2023–2030

      Segment2023202420252026202820292030CAGR (%)
      BLOOD BANKS38.3939.1640.3342.0246.850.0353.926
      CLINICAL LABORATORIES409.02422.31440.3464.39530.06573.54625.817.3
      HOME CARE SETTINGS51.0852.3154.0956.5863.5368.1873.796.4
      HOSPITALS & CLINICS963.6991.021029.161081.211224.361319.521434.046.9
      TOTAL1462.091504.81563.881644.21864.752011.272187.566.9

      Target Audience

      • Diagnostic Equipment Manufacturers : Manufacturers need France-specific market data to assess market size, growth potential, and competitive landscape for immunoassay platforms, enabling informed product development and commercialization strategies.
      • Healthcare Investment Firms : Investment professionals require detailed French market metrics and forecasts to evaluate acquisition targets, fund allocation decisions, and portfolio companies operating in the diagnostic sector.
      • Laboratory Service Providers : Clinical and reference laboratories need market insights to understand demand trends, capacity planning requirements, and technology investment priorities specific to the French healthcare market.
      • Pharmaceutical & Biotech Companies : Companies developing companion diagnostics and biomarker assays require France-specific market data to prioritize development programs and commercialization efforts in this high-growth market.
      • Healthcare Consultants & Analysts : Consulting firms and research analysts need comprehensive France market data to support client advisory services, competitive benchmarking, and strategic recommendations in the immunoassay sector.

      Key Companies in the France Immunoassay Market

      CompanyHQOwnershipStrongest segments
      PATHEON INCNetherlandsPrivate CompanyDrug Product Services (oral, sterile, packaging, lifecycle),Pharmaceutical Development Services (preclinical to clinical),Drug Substance Services (small-molecule and biologics APIs),
      ALERE INCUnited StatesPrivate CompanyInfectious disease diagnostics (rapid and serology, including ELISA and automated systems),Cardiometabolic and critical care point-of-care (blood gas, lipids, glucose, D-dimer, troponin, diabetes),Toxicology and workplace drug testing (devices, reagents, lab services, alcohol tests),
      FLUOR CORPORATIONUnited StatesPublic CompanyEnergy Solutions (oil, gas, chemicals, LNG, power, energy transition),Urban Solutions (advanced technologies, life sciences, mining and metals, infrastructure, staffing, maintenance),Mission Solutions (government, nuclear remediation, nuclear security, logistics, mission-critical O&M),
      CEPHEID INC.United StatesPrivate CompanyInfectious disease & healthcare-associated infection assays (Xpert on GeneXpert),Virology assays (including emergency use authorization tests),Oncology and genetics assays,
      IMMUCOR, INC.United StatesPrivate CompanyTransfusion (serology instruments and reagents, including NEO, Echo, Capture),Transplant & Molecular (HLA, HPA assays, Array Imaging System, BASIS, platelet-focused products),Other / Services and Ancillary Products,
      UNILABSSwitzerlandPrivate CompanyRoutine & Specialty Laboratory Testing,Medical Imaging,Pathology & Centres of Excellence (IVF, Fertility, Pregnancy, Targeted Diagnostics),
      EIKEN CHEMICAL CO., LTD.JapanPublic CompanyFecal immunochemical test (FIT) reagents and analyzers,Microbiological reagents and food/environmental microbiology,Urinalysis test strips and analyzers,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      SIEMENS HEALTHINEERS AGGermanyPublic CompanyImaging,Diagnostics,Varian (Oncology),
      DANAHERUnited StatesPublic CompanyBiotechnology (bioprocessing and related solutions),Life Sciences (analytical instruments, genomics, and lab automation),Diagnostics (clinical instruments and consumables),
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
      REVVITYUnited StatesPublic CompanyDiagnostics instruments and systems,Diagnostics reagents, assays, and consumables,Life science reagents and genomic workflow tools,
      DIASORIN S.P.A.ItalyPublic CompanyImmunodiagnostics – Infectious and Gastrointestinal Diseases,Immunodiagnostics – Endocrinology, Metabolic Disorders, Tumor Markers, Oncology,Molecular Diagnostics – Simplexa and Congenital CMV,
      BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics,Life Science Research Tools,Other / Informatics & Software,
      QUIDELORTHO CORPORATIONUnited StatesPublic CompanyLabs (clinical chemistry and immunoassay),Transfusion Medicine,Point of Care,
      BIOMÉRIEUXFrancePublic CompanyClinical microbiology & AST (VITEK, CHROMID, ETEST, culture media, BACT/ALERT),Syndromic and molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS),Immunoassays & biomarkers (VIDAS, Hybiome CLIA),
      QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Molecular diagnostics assays (TB, immune response, oncology, sexual and reproductive health),Research PCR and enzymes (qPCR, digital PCR, RT-PCR, configured solutions),
      SYSMEX CORPORATIONJapanPublic CompanyHematology analyzers & reagents,Coagulation diagnostics,Urinalysis, blood gas, electrolyte,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.ChinaPublic CompanyPatient monitoring and life support (monitoring, ventilators, defibrillation, AED, anesthesia),Ultrasound and medical imaging (ultrasound, radiology, endoscope camera system),In-vitro diagnostics (CLIA, chemistry, hematology, laboratory diagnostics),

      PATHEON INC

      Patheon Inc. is a Netherlands-based pharmaceutical manufacturing company with 9,100 employees. Operating as a private company, it provides contract development and manufacturing services to the pharmaceutical industry.

      ALERE INC

      Alere Inc. is a United States-based diagnostics company founded in 1981 with 9,700 employees. Operating as a private company, it specializes in rapid diagnostic testing solutions for healthcare markets.

      FLUOR CORPORATION

      Fluor Corporation is a United States-based engineering and construction company founded in 1912 with 22,995 employees. As a public company, it provides design, engineering, procurement, and construction services across multiple industries.

      CEPHEID INC.

      Cepheid Inc. is a United States-based molecular diagnostics company founded in 1996 with 1,700 employees. Operating as a private company, it develops and manufactures automated molecular testing systems.

      IMMUCOR, INC.

      Immucor, Inc. is a United States-based immunohematology company founded in 1982 with 1,125 employees. As a private company, it specializes in blood bank and transfusion medicine diagnostic solutions.

      UNILABS

      Unilabs is a Switzerland-based clinical laboratory services company founded in 1987 with 1,897 employees. As a private company, it operates diagnostic laboratories across multiple European countries.

      EIKEN CHEMICAL CO., LTD.

      Eiken Chemical Co., Ltd. is a Japan-based diagnostics and pharmaceutical company founded in 1939 with 696 employees. As a public company, it manufactures in vitro diagnostic reagents and pharmaceutical products.

      ABBOTT

      Abbott is a United States-based healthcare company founded in 1888 with 115,000 employees. As a public company, it develops and manufactures diagnostics, medical devices, pharmaceuticals, and nutritional products.

      SIEMENS HEALTHINEERS AG

      Siemens Healthineers AG is a Germany-based medical technology company founded in 1896 with 72,369 employees. As a public company, it manufactures and distributes diagnostic imaging, laboratory diagnostics, and point-of-care testing systems.

      DANAHER

      Danaher is a United States-based conglomerate founded in 1969 with 59,000 employees. As a public company, it operates across multiple sectors including life sciences, diagnostics, and environmental solutions.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a United States-based life sciences company founded in 1956 with 125,000 employees. As a public company, it provides laboratory equipment, reagents, and analytical instruments globally.

      REVVITY

      Revvity is a United States-based life sciences and diagnostics company founded in 1937 with 11,000 employees. As a public company, it manufactures and distributes analytical instruments and reagents for research and diagnostics.

      DIASORIN S.P.A.

      DiaSorin S.p.A. is an Italy-based diagnostics company founded in 1968 with 3,242 employees. As a public company, it develops and manufactures in vitro diagnostic products for clinical laboratories.

      BIO-RAD LABORATORIES, INC.

      Bio-Rad Laboratories, Inc. is a United States-based life sciences company founded in 1952 with 7,450 employees. As a public company, it manufactures and distributes reagents, instruments, and quality control products for clinical and research laboratories.

      QUIDELORTHO CORPORATION

      QuidelOrtho Corporation is a United States-based diagnostics company founded in 1979 with 6,500 employees. As a public company, it develops and manufactures rapid diagnostic tests and laboratory instruments.

      BIOMÉRIEUX

      bioMérieux is a France-based diagnostics company founded in 1963 with 14,894 employees. As a public company, it specializes in in vitro diagnostics for infectious diseases, industrial microbiology, and clinical diagnostics.

      QIAGEN

      QIAGEN is a Netherlands-based molecular diagnostics company founded in 1984 with 5,500 employees. As a public company, it develops and manufactures sample preparation and molecular testing solutions.

      SYSMEX CORPORATION

      Sysmex Corporation is a Japan-based diagnostics company founded in 1968 with 10,861 employees. As a public company, it manufactures and distributes hematology, hemostasis, and clinical chemistry analyzers.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a United States-based life sciences and diagnostics company founded in 1999 with 18,000 employees. As a public company, it provides analytical instruments, software, and services for research and diagnostics.

      SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.

      Shenzhen Mindray Bio-Medical Electronics Co., Ltd. is a China-based medical device company founded in 1991 with 21,288 employees. As a public company, it manufactures and distributes diagnostic imaging, patient monitoring, and laboratory instruments globally.

      Reasons to Buy this Report

      • Market-Specific Sizing Data : Access precise valuation metrics for France's immunoassay market with verified 2025 baseline (USD 1,316.11M) and 2030 forecast (USD 1,854.62M), enabling accurate business planning and investment decisions.
      • Competitive Positioning Intelligence : Understand France's market dynamics relative to global trends, with the 7.1% CAGR outperforming global average, helping identify growth opportunities and competitive advantages in this high-performing market.
      • Regulatory & Healthcare Landscape Insights : Gain detailed understanding of France's advanced healthcare infrastructure, diagnostic adoption patterns, and regulatory environment specific to immunoassay products and services.
      • Strategic Market Entry Planning : Leverage France-specific market data to develop targeted go-to-market strategies, identify key customer segments, and optimize resource allocation for market penetration and expansion.
      • Investment & Partnership Opportunities : Identify high-growth segments and partnership prospects within France's expanding immunoassay sector, supported by comprehensive market forecasts and trend analysis through 2030.

      Frequently asked questions

      What is the current size of France's immunoassay market?

      France's immunoassay market is valued at USD 1,316.11 million in 2025, with verified data confirming this market size across the country's diagnostic and clinical laboratory sectors.

      What is the projected size of France's immunoassay market by 2030?

      France's immunoassay market is forecast to reach USD 1,854.62 million by 2030, representing significant expansion from the 2025 baseline.

      What is the CAGR for France's immunoassay market?

      France's immunoassay market is expected to grow at a compound annual growth rate of 7.1% between 2025 and 2030, outperforming the global average.

      Why is France's immunoassay market growing faster than the global average?

      France's 7.1% CAGR exceeds the global 6.1% rate due to advanced healthcare infrastructure, high diagnostic spending, aging demographics, and strong adoption of precision medicine technologies.

      Which sectors drive immunoassay demand in France?

      France's immunoassay demand is driven by clinical laboratories, hospitals, diagnostic centers, and point-of-care testing facilities responding to chronic disease management and early detection needs.

      RESEARCH METHODOLOGY

      This study analyzes key market dynamics, including drivers, opportunities, restraints, and challenges, as well as major players’ strategies. It also monitors developments among leading players, including acquisitions, product launches, expansions, agreements, and partnerships. Additionally, the study examines the immunoassay market’s competitive landscape by evaluating market participants against criteria within the overarching categories of business and product strategy. To estimate market size, the study employed both top-down and bottom-up approaches. The market breakdown and data triangulation methods were used to assess segment and subsegment sizes.
      The four steps involved in estimating the market size are as follows:

      Secondary Research

      In the secondary research process, various secondary sources such as annual reports, press releases, and investor presentations of companies; white papers; certified publications; articles by recognized authors; gold- and silver-standard websites; regulatory bodies; and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study.

      Primary Research

      In the primary research process, we interviewed various sources from the supply and demand sides to obtain qualitative and quantitative information for this report. Primary sources were industry experts from core and related industries, as well as preferred suppliers, manufacturers, distributors, technology developers, researchers, and organizations across all segments of this industry’s value chain. We conducted in-depth interviews with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.

      The following is a breakdown of the primary respondents:

      Immunoassay Market Size, and Share

      Note 1: C-level executives include Chief Executive Officers (CEOs), Chief Financial Officers (CFOs), Chief Operating Officers (COOs), and Vice Presidents (VPs).
      Note 2: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
      Note 3: Companies are classified into tiers based on their total revenue as of 2025. The tiers are as follows: Tier 1 = >USD 10 billion, Tier 2 = USD 1 billion to USD 10 billion, and Tier 3 = <USD 1 billion.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      For global market value, we calculated annual revenue figures using revenue mapping for major product manufacturers and OEMs active in the global immunoassay market. We identified all major product manufacturers at the global and/or country/regional level. We mapped revenue for the respective business segments/subsegments of the major players. Additionally, the global market was split into various segments and subsegments:

      • List of major players in the immunoassay market by region or country
      • Product mapping of various immunoassay manufacturers at the regional and/or country level
      • Mapping of annual revenue generated by listed major players from immunoassay products (or the nearest reported business unit/product category)
      • Extrapolation of the revenue mapping of the listed major players to derive the global market size of the respective business segments, in terms of value
      • Summation of revenue of all companies to arrive at the global immunoassay market size

      The data above was consolidated, supplemented with detailed inputs and analysis from MarketsandMarkets, and presented in this report.

      Immunoassay Market: Top-Down and Bottom-Up Approach

      Immunoassay Market Top Down and Bottom Up Approach

      Data Triangulation

      After determining the overall market size using the market size estimation processes, we split the market into several segments and subsegments. To complete the overall market engineering process and arrive at precise statistics for each market segment and subsegment, we used data triangulation and market breakdown procedures, where applicable. We triangulated the data by examining factors and trends from both the demand and supply sides of the immunoassay industry.

      Market Definition

      An immunoassay is a biochemistry-based test that quantifies the presence or concentration of an analyte. An analyte can be a large protein or antibody produced due to an infection. Immunoassays have become popular and well-established procedures in laboratories. They provide quick, accurate, and precise results. This technique is mostly used in clinical diagnostics, drug monitoring, drug discovery, and food testing.

      Key Stakeholders

      • Manufacturers and vendors of immunoassay instruments and consumables
      • Immunoassay product manufacturers
      • Pharmaceutical & biopharmaceutical players
      • Diagnostic associations
      • Research associations involved in infectious and chronic disease research
      • Various research and consulting firms
      • Distributors of immunoassay instruments and consumables
      • Contract manufacturers of immunoassays
      • Healthcare institutions
      • Research institutes
      • Clinical laboratories

      Report Objectives

      • To describe, segment, and forecast the immunoassay market by product, technology, specimen, application, end user, and region in terms of value
      • To forecast the size of the immunoassay market in five main regions (along with their respective key countries): North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, in terms of value
      • To provide detailed information about the factors (drivers, restraints, opportunities, and challenges) influencing market growth
      • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall immunoassay market
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To profile the key players in the immunoassay market and comprehensively analyze their core competencies and market shares
      • To analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, partnerships, and R&D activities of the leading players in the market
      • To benchmark players within the immunoassay market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings

      Available customizations:

      Based on the market data provided, MarketsandMarkets offers customizations tailored to your company’s specific needs. The following customization options are available for the report:

      Geographict Analysis

      • Further breakdown of the Rest of Europe immunoassay market into Switzerland, Denmark, Austria, and others

      • Further breakdown of the Rest of Asia Pacific immunoassay market into Hong Kong, Taiwan, and others

      • Further breakdown of the Rest of Latin America immunoassay market into Argentina, Colombia, Chile, Ecuador, and others

      • Further breakdown of the Southeast Asian immunoassay market into Malaysia, Singapore, Australia, New Zealand, and others

      Competitive Landscape Assessment

      • Market Share Analysis, by region (North America and Europe), which provides the details about the share of the top 3 to 5 key players in the immunoassay market

      • Competitive leadership mapping for established players in the US

      Get the Full Immunoassay Market Report

      Full forecast, segment splits, and company analysis for all Immunoassay Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status